Overview
A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.
Background
A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.
Indication
Netarsudil is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension .
Associated Conditions
- Increased Intra Ocular Pressure (IOP)
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/05/14 | N/A | ENROLLING_BY_INVITATION | University Hospital Dubrava | ||
2025/05/07 | N/A | ENROLLING_BY_INVITATION | University Hospital Dubrava | ||
2025/03/07 | Phase 4 | Recruiting | East Coast Institute for Research | ||
2024/06/10 | Phase 4 | Recruiting | |||
2024/06/04 | Phase 2 | Not yet recruiting | |||
2024/05/01 | Phase 2 | Active, not recruiting | |||
2023/09/13 | Phase 1 | Not yet recruiting | |||
2022/12/21 | Phase 2 | Active, not recruiting | Wills Eye | ||
2022/03/17 | Phase 4 | Completed | Aerie Pharmaceuticals | ||
2021/07/29 | Phase 4 | UNKNOWN |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
Authorised | 11/19/2019 | ||
Authorised | 1/7/2021 | ||
Authorised | 1/7/2021 | ||
Authorised | 1/7/2021 | ||
Authorised | 11/19/2019 |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| RHOPRESSA OPHTHALMIC SOLUTION, 0.02% w/v | SIN16816P | SOLUTION, STERILE | 0.02% w/v | 7/4/2023 | |
| ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V | SIN16818P | SOLUTION, STERILE | 0.02% w/v | 7/4/2023 |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||